Cerba Research is uniquely positioned to support your cell & gene therapy trial with a wide range of in-house laboratory services, supported by bespoke logistics solutions. We are also able to support sponsors with their assay development, including our regulatory and IVDR certification capabilities. One IVDR example is related to AAV ( ADA) ELISA assay.

Cerba Research has conducted ~80 hematological malignancy trials within the last 5 years alone. Download our fact sheet and discover our hematological malignancies trial portfolio with cutting-edge laboratory solutions.

Cerba Research has conducted nearly 200 oncology trials within the last 5 years alone, with 55%+ being solid tumors such as lung, breast, and colorectal cancers. The central and specialty laboratories’ expertise includes specialized assays such as next-generation sequencing (NGS), flow cytometry (FCM), immunohistochemistry (IHC), AI in image analysis, and NanoString®. Check our latest fact sheet to learn more about our highlights and capabilities.

Cerba Research has conducted nearly 200 oncology trials within the last 5 years alone. Its experience extends to both solid and liquid tumors and includes specialized assays such as next-generation sequencing (NGS), flow cytometry (FCM), immunohistochemistry (IHC), and NanoString®. Check our latest fact sheet to learn more about our highlights and capabilities.

Experience the unparalleled activity of Cerba Research’s Infectious Diseases (ID) therapy sector, boasting a remarkable track record of over 600 executed trials in just the last 5 years.

Discover the extraordinary world of rare diseases, where uniqueness defines the landscape. While these conditions may lack a singular definition, they encompass a myriad of fascinating conditions waiting to be understood and treated.

Cerba Research Montpellier (CRM), a leader in histopathology and part of the Cerba Research group, is revolutionizing solid tumor clinical trials with our cutting-edge NanoString® platforms. Specializing in multiplex immunofluorescence for FFPE tissues, our lab now offers unparalleled transcriptomic and proteomic analysis capabilities.

Of all types of cancer, lung cancer caused more deaths worldwide than any other type of cancer. It also causes more deaths than breast and colorectal cancers combined. Patients with the most common lung cancer, non-small cell lung cancer (NSCLC), have higher survival rates than patients with small-cell lung cancer (SCLC), but the outcomes for both remain bleak. According to the National Cancer Institute, the five-year survival rate for NSCLC between 2004 and 2010 was 20.7% compared to only 6.3% for SCLC.2

NSCLC patients also have more promising and more precise, treatment options today compared to even 10 years ago. Advances in biomarker and precision medicine have led to the development of immunotherapies and targeted novel treatments that have the potential to improve patient outcomes. In the United States, the FDA has approved dozens of biomarker-driven therapies for NSCLC, including ALK, EGFR, and ROS1 inhibitors. Meanwhile, more than 1,200 treatments are in development.

Discover the latest trends in precision medicine for NSCLC in this white paper

This presentation was given by Marie Gerus-Durand, Principal Scientist & Validation Engineer at Cerba Research Montpellier at the JMP Discovery Summit Europe.

Cerba Research is a global company providing high-quality, specialized analytical and diagnostic solutions for clinical trials. Cerba Research Montpellier develops customized immunohistochemistry protocols to detect the expression of selected targets on patients’ tissue sections.

To be used in clinical trials, these protocols must meet the regulatory agencies’ criteria to ensure that the protocol will allow consistent results on precious patients’ samples. With the diversity of parameters evaluated and the types of evaluation possible in implementing these custom protocols, automating data analysis became a need.

Thanks to various JMP® tools, we have developed an automated analysis that saves time and homogenizes protocol performance reports by including statistical and graphical data in a Dashboard. This process, submitted as JMP Add-in, has been incorporated into our user workflows, thus facilitating our procedures.

Watch the full presentation here

In immuno-oncology (I/O), meeting budget and timeline expectations in the journey from translational research to commercialization is a challenge. You need expert, integrated central laboratory and diagnostic solutions delivered by top scientists who will help you assess needs and generate early insights that optimize your protocol.

What else should you look for in a clinical laboratory partner? Along with access to a sizable patient database, impeccable performance across the globe, and I/O experience, three main testing capabilities are mandatory for success in this field: immunohistochemistry, flow cytometry, and next-generation sequencing.